Home

Investors & News

Corporate Profile

Tengion’s first clinical program is the Neo-Kidney Augment™, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease (CKD). According to the United States Renal Data System, there are approximately 26 million adults in the U.S. who have chronic kidney disease (CKD), and there are 100,000 new patients who start on dialysis each year. $39 billion in direct U.S. costs each year are attributable to patients with end-stage renal disease, which is associated with an approximate 20% mortality rate per year and an average life expectancy of a patient initiating dialysis of approximately four years. The Neo-Ki... More >>

Recent News More >>
Upcoming Events More >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.01
Change (%)-0.00 (0.00%)
Volume768,410
Data as of 11/21/14 3:51 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
November 14, 2014
Tengion Provides Clinical Update and Reports Third Quarter 2014 Financial Results and Cash Position
WINSTON-SALEM, N.C., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended September 30, 2014. "We remain committed to realizing the full value of our Organ Regeneration Platform and to maximizing value for our stakeholders and, therefore, in September, we announced that we retained Jefferies LLC as an executive financial advisor to assist us with revie... 
September 22, 2014
Tengion Retains Jefferies to Explore Strategic Options for the Company
WINSTON-SALEM, N.C., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that the Company, with the support of its Board of Directors, is exploring all strategic options to maximize the value of its assets and has retained Jefferies LLC as exclusive financial advisor to assist it with reviewing and structuring potential strategic transactions. "We believe this decision increases our ability to realize the value of our Organ Regene...